RxDoctor Payments DataLook up a doctor →

Robert Eckart, DO

Clinical Cardiac Electrophysiology · Sarasota, FLNPI 1366479404

Payments from drug & device makers

$478,786in general payments, 2019–2025

Across 394 payments — averaging $1215.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$459K
  • Abbott$17K
  • Medtronic$984
  • Philips North America LLC$850
  • Biosense Webster, Inc.$195
  • Impulse Dynamics (USA) Inc.$184
  • plus $748 from 19 others

What the payments were for

  • Speaking & faculty fees$50,62587%
  • Travel & lodging$1,6183%
  • Food & beverage$5,84510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$478,786 in reported general payments places this provider in the 90th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,550,508
Medicare patients
2,113
Services billed
8,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban233$219,856
XareltoRivaroxaban66$68,978
EntrestoSacubitril/Valsartan17$19,826
Dofetilide28$6,993
BrilintaTicagrelor12$6,789
SotalolSotalol Hcl292$4,994
Flecainide Acetate63$3,241
Propafenone Hcl50$2,648
Metoprolol Succinate216$2,522
Digoxin128$2,144
Amiodarone Hcl90$1,555
ClopidogrelClopidogrel Bisulfate89$925
Mexiletine Hcl11$787
Cephalexin194$702
Losartan Potassium36$608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$142$219,856233 claims
NovartisEntresto$26$19,82617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →